US expert committee recommends Pfizer COVID vaccine approval | Inquirer News

US expert committee recommends Pfizer COVID vaccine approval

/ 08:08 AM December 11, 2020

WASHINGTON – An expert committee convened by the US Food and Drug Administration voted heavily in favor of recommending the Pfizer-BioNTech COVI-19 vaccine for emergency use approval on Thursday.

The final voting tally was 17 in favor, four against and one abstention.

Article continues after this advertisement

The committee was tasked with answering whether, “based on the totality of scientific evidence available, do the benefits of the Pfizer-BioNTech COVID-19 vaccine outweigh its risk for use in individuals 16 years of age and older?”

FEATURED STORIES

The vote by the independent experts and researchers, including infectious disease specialists, biostatisticians and other scientists, isn’t binding but the FDA is expected to follow the recommendation within the coming days.

Britain, Canada, Bahrain and Saudi Arabia have already approved the vaccine, the first in the world to complete a large-scale, phase 3 clinical trial.

Article continues after this advertisement

Russian and Chinese vaccines are already being administered on a large scale, but without having completed comparable clinical trials.

Article continues after this advertisement

The full results of the trial, which included nearly 44,000 people, were published Thursday in the New England Journal of Medicine, another major milestone.

Article continues after this advertisement

These confirmed the vaccine was 95 percent effective with no serious safety issues, an outcome that was described in an accompanying editorial as a “triumph.”

pfizer vaccine covid-19 biontech

In this illustration file photo taken on November 23, 2020 showing a bottle reading “Vaccine COVID-19” and a syringe next to the Pfizer and BioNtech logos. – An expert committee convened by the US Food and Drug Administration on December 10, 2020, voted heavily in favor of recommending the Pfizer-BioNTech Covid-19 vaccine for emergency use approval. (Photo by JOEL SAGET / AFP)

Pfizer scientist Kathrin Jansen told the panel this was a result of the innovative messenger RNA technology behind the vaccine, an approach that has never before been approved.

Article continues after this advertisement

Britain on Wednesday reported that two health care workers developed significant allergic reactions to the vaccine as the country rolled out its massive drive Tuesday.

The FDA will therefore include a warning label on the vaccine if it’s approved, the agency’s Marion Gruber said.

gsg
Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

For more news about the novel coronavirus click here.
What you need to know about Coronavirus.
For more information on COVID-19, call the DOH Hotline: (02) 86517800 local 1149/1150.

The Inquirer Foundation supports our healthcare frontliners and is still accepting cash donations to be deposited at Banco de Oro (BDO) current account #007960018860 or donate through PayMaya using this link.

TAGS: approved, COVID-19, FDA, Pfizer, vaccine

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.